On the other hand, a recent study described the firstSIRT5 activator that has been used in the context of cancer, specificallyPDAC, where SIRT5 plays an oncosuppressor role.130 This indicates that there is increased interest in developingboth inhibitors and activators, thereby enabling a better understandingof SIRT5’s function and paving the way to personalized approaches.In the next section, we will initially examine the most relevant SIRT5inhibitors and then discuss a recently reported activator. The gene discussed is SIRT5; the disease is cancer.